22.00
-0.32 (-1.43%)
| Previous Close | 22.32 |
| Open | 22.00 |
| Volume | 90,514 |
| Avg. Volume (3M) | 75,962 |
| Market Cap | 227,827,792 |
| Price / Sales | 1.80 |
| Price / Book | 24.10 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Profit Margin | -54.28% |
| Operating Margin (TTM) | -50.47% |
| Diluted EPS (TTM) | -0.270 |
| Quarterly Revenue Growth (YOY) | 21.20% |
| Total Debt/Equity (MRQ) | 577.44% |
| Current Ratio (MRQ) | 2.22 |
| Operating Cash Flow (TTM) | -41.94 M |
| Levered Free Cash Flow (TTM) | -31.89 M |
| Return on Assets (TTM) | -23.33% |
| Return on Equity (TTM) | -1,454.41% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Biodesix, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 52.11% |
| % Held by Institutions | 36.46% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |